Biogen Inc. (BVMF:BIIB34)

Biogen Statistics

Total Valuation

Biogen has a market cap or net worth of BRL 125.45 billion. The enterprise value is 139.38 billion.

Market Cap	125.45B
Enterprise Value	139.38B

Important Dates

The next estimated earnings date is Thursday, February 12, 2026.

Earnings Date	Feb 12, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+0.36%
Shares Change (QoQ)	+0.27%
Owned by Insiders (%)	0.17%
Owned by Institutions (%)	90.07%
Float	146.31M

Valuation Ratios

The trailing PE ratio is 14.63 and the forward PE ratio is 12.24.

PE Ratio	14.63
Forward PE	12.24
PS Ratio	2.34
PB Ratio	1.29
P/TBV Ratio	9.87
P/FCF Ratio	10.22
P/OCF Ratio	9.59
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 7.47, with an EV/FCF ratio of 11.35.

EV / Earnings	16.26
EV / Sales	2.61
EV / EBITDA	7.47
EV / EBIT	9.95
EV / FCF	11.35

Financial Position

The company has a current ratio of 2.72, with a Debt / Equity ratio of 0.36.

Current Ratio	2.72
Quick Ratio	1.77
Debt / Equity	0.36
Debt / EBITDA	1.87
Debt / FCF	2.86
Interest Coverage	10.18

Financial Efficiency

Return on equity (ROE) is 9.31% and return on invested capital (ROIC) is 6.92%.

Return on Equity (ROE)	9.31%
Return on Assets (ROA)	5.75%
Return on Invested Capital (ROIC)	6.92%
Return on Capital Employed (ROCE)	10.21%
Revenue Per Employee	7.05M
Profits Per Employee	1.13M
Employee Count	7,605
Asset Turnover	0.35
Inventory Turnover	1.01

Taxes

In the past 12 months, Biogen has paid 1.57 billion in taxes.

Income Tax	1.57B
Effective Tax Rate	15.52%

Stock Price Statistics

The stock price has decreased by -16.82% in the last 52 weeks. The beta is 0.15, so Biogen's price volatility has been lower than the market average.

Beta (5Y)	0.15
52-Week Price Change	-16.82%
50-Day Moving Average	128.40
200-Day Moving Average	155.27
Relative Strength Index (RSI)	59.46
Average Volume (20 Days)	21

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	3.42

Income Statement

In the last 12 months, Biogen had revenue of BRL 53.65 billion and earned 8.57 billion in profits. Earnings per share was 58.49.

Revenue	53.65B
Gross Profit	41.07B
Operating Income	14.10B
Pretax Income	10.15B
Net Income	8.57B
EBITDA	18.17B
EBIT	14.10B
Earnings Per Share (EPS)	58.49

Balance Sheet

The company has 21.11 billion in cash and 35.12 billion in debt, giving a net cash position of -14.01 billion.

Cash & Cash Equivalents	21.11B
Total Debt	35.12B
Net Cash	-14.01B
Net Cash Per Share	n/a
Equity (Book Value)	97.04B
Book Value Per Share	661.45
Working Capital	30.09B

Cash Flow

In the last 12 months, operating cash flow was 13.08 billion and capital expenditures -795.15 million, giving a free cash flow of 12.28 billion.

Operating Cash Flow	13.08B
Capital Expenditures	-795.15M
Free Cash Flow	12.28B
FCF Per Share	n/a

Margins

Gross margin is 76.56%, with operating and profit margins of 26.28% and 15.98%.

Gross Margin	76.56%
Operating Margin	26.28%
Pretax Margin	18.92%
Profit Margin	15.98%
EBITDA Margin	33.87%
EBIT Margin	26.28%
FCF Margin	22.89%

Dividends & Yields

Biogen does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.36%
Shareholder Yield	-0.36%
Earnings Yield	6.83%
FCF Yield	9.79%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Biogen has an Altman Z-Score of 3 and a Piotroski F-Score of 6.

Altman Z-Score	3
Piotroski F-Score	6